Hep C Drug Trends: Cost Driver In 2014, But “Leveling Off” Coming, CMS Actuaries Say
This article was originally published in RPM Report
CMS actuaries attribute an increase in health spending in 2014 to the expansion of Medicaid and private health insurance coverage and rapid growth in retail drug spending, particularly for new hep C drugs.
You may also be interested in...
Retail drug spending rose just 1.3% in 2016, following growth rates of 8.9% and 12.4% in 2015 and 2014, respectively. Moderating trend is reported just ahead of two congressional hearings on drug pricing.
FDA and NIH are looking to spark research on approaches to reduce use of benzodiazepines and to help mitigate issues with withdrawal associated with the widely prescribed therapies.
Three of the US FDA’s former leaders believe the agency is coming through COVID with its reputation intact. They still support making the agency independent of the broader Health & Human Services Department, but the urgency may be gone.